Animal models for modeling pancreatic cancer and novel drug discovery

被引:23
作者
Bisht, Savita [1 ]
Feldmann, Georg [1 ]
机构
[1] Univ Hosp Bonn, Dept Internal Med 3, Bonn, Germany
基金
欧盟地平线“2020”;
关键词
Pancreatic cancer; translational research; patient-derived xenografts; genetically engineered mouse models; MOUSE XENOGRAFT MODELS; DUCTAL ADENOCARCINOMA; IN-VIVO; ULTRASTRUCTURAL ANALYSIS; ONCOGENIC KRAS; CELL-LINES; STEM-CELL; GENOMIC CHARACTERIZATION; TUMOR XENOGRAFTS; NAB-PACLITAXEL;
D O I
10.1080/17460441.2019.1566319
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Despite the introduction of novel therapeutic regimens for advanced stages of pancreatic cancer, long-term survival and overall outcome for patients are still very poor. Suitable small animal models are a prerequisite for better understanding of underlying pathophysiology and for translational studies designed to uncover novel therapeutic targets and to evaluate therapy regimens on a preclinical level. Areas covered: Genetically engineered mouse models as well as syngenic and xenotransplantation models are summarized and critically discussed with respect to their value for pancreatic cancer translational research. Expert opinion: Mouse models of pancreatic cancer represent a valuable tool for translational studies and are indispensable in order to develop novel potent drugs against pancreatic cancer. More complex genetically engineered mouse models are being developed to cover the complex genomic alterations found in human pancreatic cancers and to enable studies correlating genotype with response to specific therapeutic interventions. Another promising area of research in this field is the refinement and further development of humanized patient-derived xenograft models.
引用
收藏
页码:127 / 142
页数:16
相关论文
共 141 条
  • [1] Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.
    Abolhassani, Mohammad
    Guais, Adeline
    Sanders, Edward
    Campion, Frederic
    Fichtner, Iduna
    Bonte, Jacques
    Baronzio, Gianfranco
    Fiorentini, Giammaria
    Israel, Maurice
    Schwartz, Laurent
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1331 - 1342
  • [2] Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
    Aguirre, AJ
    Bardeesy, N
    Sinha, M
    Lopez, L
    Tuveson, DA
    Horner, J
    Redston, MS
    DePinho, RA
    [J]. GENES & DEVELOPMENT, 2003, 17 (24) : 3112 - 3126
  • [3] Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
    Aguirre, Andrew J.
    Hruban, Ralph H.
    Raphael, Benjamin J.
    [J]. CANCER CELL, 2017, 32 (02) : 185 - +
  • [4] Novel agents for advanced pancreatic cancer
    Akinleye, Akintunde
    Iragavarapu, Chaitanya
    Furqan, Muhammad
    Cang, Shundong
    Liu, Delong
    [J]. ONCOTARGET, 2015, 6 (37) : 39521 - 39537
  • [5] Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites
    Allaway, Robert J.
    Fischer, Dawn A.
    de Abreu, Francine B.
    Gardner, Timothy B.
    Gordon, Stuart R.
    Barth, Richard J.
    Colacchio, Thomas A.
    Wood, Matthew
    Kacsoh, Balint Z.
    Bouley, Stephanie J.
    Cui, Jingxuan
    Hamilton, Joanna
    Choi, Jungbin A.
    Lange, Joshua T.
    Peterson, Jason D.
    Padmanabhan, Vijayalakshmi
    Tomlinson, Craig R.
    Tsongalis, Gregory J.
    Suriawinata, Arief A.
    Greene, Casey S.
    Sanchez, Yolanda
    Smith, Kerrington D.
    [J]. ONCOTARGET, 2016, 7 (13) : 17087 - 17102
  • [6] Zebrafish as a cancer model system
    Amatruda, JF
    Shepard, JL
    Stern, HM
    Zon, LI
    [J]. CANCER CELL, 2002, 1 (03) : 229 - 231
  • [7] Multi-modality imaging-monitored creation of rat orthotopic pancreatic head cancer with obstructive jaundice
    Bai, Zhibin
    Shi, Yaoping
    Wang, Jianfeng
    Qiu, Longhua
    Teng, Gaojun
    Zhang, Feng
    Yang, Xiaoming
    [J]. ONCOTARGET, 2017, 8 (33) : 54277 - 54284
  • [8] Baker LA, 2019, METHODS MOL BIOL, V1882, P117, DOI 10.1007/978-1-4939-8879-2_10
  • [9] Baker LA, 2019, METHODS MOL BIOL, V1882, P97, DOI 10.1007/978-1-4939-8879-2_9
  • [10] Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse
    Bardeesy, N
    Aguirre, AJ
    Chu, GC
    Cheng, KH
    Lopez, LV
    Hezel, AF
    Feng, B
    Brennan, C
    Weissleder, R
    Mahmood, U
    Hanahan, D
    Redston, MS
    Chin, L
    DePinho, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) : 5947 - 5952